Avrobio (NASDAQ:AVRO) announced its earnings results on Thursday. The company reported ($0.57) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.02, Fidelity Earnings reports.
AVRO opened at $15.39 on Friday. The firm has a market cap of $349.17 million, a P/E ratio of -4.25 and a beta of 2.63. The firm has a 50-day moving average of $14.77 and a 200 day moving average of $17.14. Avrobio has a fifty-two week low of $11.85 and a fifty-two week high of $31.00.
Several equities analysts recently weighed in on AVRO shares. Zacks Investment Research upgraded shares of Avrobio from a “sell” rating to a “hold” rating in a research report on Wednesday, October 30th. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Avrobio in a research report on Friday. Cowen restated a “buy” rating on shares of Avrobio in a research report on Monday, July 15th. Wedbush restated an “outperform” rating and set a $43.00 price target on shares of Avrobio in a research report on Friday, August 9th. Finally, ValuEngine upgraded shares of Avrobio from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $28.92.
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Recommended Story: Producer Price Index (PPI)
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.